RxDoctor Payments Data

Frieda Gear, PA

Physician Assistant · Madison, WINPI 1982980397

Payments from drug & device makers

$1,751in general payments, 2019–2025

Across 78 payments — averaging $22.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$401
  • Alkermes, Inc.$365
  • Teva Pharmaceuticals USA, Inc.$202
  • Lundbeck LLC$120
  • Otsuka America Pharmaceutical, Inc.$104
  • Johnson & Johnson$101
  • plus $457 from 9 others

What the payments were for

  • Food & beverage$1,751100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,751 in reported general payments places this provider in the 90th percentile of 2,804 physician assistant providers in Wisconsin.

See all physician assistant providers in Wisconsin

Medicare billing

Part B allowed, 2024
$10,114
Medicare patients
12
Services billed
122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate12$39,623
RexultiBrexpiprazole14$18,434
VraylarCariprazine Hcl11$18,187
TrintellixVortioxetine Hydrobromide12$9,777
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl16$2,057
Clomipramine Hcl25$820
Fluoxetine Hcl19$648
Sertraline Hcl48$449
Desvenlafaxine Succinate ErDesvenlafaxine Succinate16$369
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine13$367
Hydroxyzine Hcl22$324
Risperidone17$298
Aripiprazole23$262
Lamotrigine22$255
Olanzapine12$239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$101$39,62312 claims
Otsuka America Pharmaceutical, Inc.Rexulti$104$18,43414 claims
AbbVieVraylar$401$18,18711 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$73$9,77712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,804 physician assistant providers in Wisconsin.

Other physician assistant in Madison

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →